Next Article in Journal
Integrative Molecular and Immune Profiling in Advanced Unresectable Melanoma: Tumor Microenvironment and Peripheral PD-1+ CD4+ Effector Memory T-Cells as Potential Markers of Response to Immune Checkpoint Inhibitor Therapy
Next Article in Special Issue
Effect of Conization Prior to Radical Hysterectomy on Overall and Progression-Free Survival in Early-Stage Cervical Cancer: A Propensity Score-Matched Analysis
Previous Article in Journal
Effects of Massage Therapy in Breast Cancer Survivors with Mastectomy: Systematic Review
Previous Article in Special Issue
Beliefs and Perceptions in Attending the Cervical Screening: The COMUNISS Project Experience
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Impact of HPV Testing Based on the 2020 Update of the German Cervical Cancer Screening Program—Data from a Retrospective Monocentric Study

by
Leonard Jung
1,2,*,
Gilbert Georg Klamminger
3,
Meletios P. Nigdelis
4 and
Elke Eltze
1,2
1
Institute of Pathology, Saarbrücken-Rastpfuhl, 66113 Saarbrücken, Germany
2
Department of General and Special Pathology, Saarland University (USAAR), Saarland University Medical Center (UKS), 66421 Homburg, Germany
3
Department of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany
4
Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center (UKS), 66424 Homburg, Germany
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(12), 2024; https://doi.org/10.3390/cancers17122024
Submission received: 6 April 2025 / Revised: 28 May 2025 / Accepted: 12 June 2025 / Published: 17 June 2025
(This article belongs to the Special Issue Cervical Cancer: Screening and Treatment in 2024-2025)

Simple Summary

In 2020, Germany transitioned from annual cytological screening to a combination screening for cervical cancer in women aged 35 and older. The updated Cervical Cancer Screening Program, now conducted every three years, includes both a Pap smear and an HPV test. To evaluate the impact of this new protocol on the detection of high-grade cervical dysplasia (CIN II/III) and the frequency of colposcopic and histological examinations, we conducted a retrospective, single-center study. We present relevant screening outcomes from women examined between 2018–2019 and 2020–2021. Consistent with previous international studies, our findings show a higher number of high-grade dysplasia as well as a higher number of colposcopic procedures following the implementation of the new screening program.

Abstract

Background/Objectives: Since 2020, Germany has replaced its annual cytological screening for cervical cancer in women aged 35 and older with a combination screening program. This updated protocol, conducted every three years, includes both a cervical Pap smear and an HPV (human papillomavirus) test. In addition, the 2020 update of the German Cervical Cancer Screening Program mandates a more timely follow-up for certain abnormal findings compared to the previous approach. Methods: Results of cytologic, colposcopic, and histologic examinations between 2018 and 2021 were retrospectively retrieved from the electronic patient records of the Institute of Pathology Saarbrücken Rastpfuhl in order to present relevant findings within the years 2018–2019 and 2020–2021. The present study included all women who received appropriate follow-up based on the corresponding underlying screening modality. Results: Our reporting considered data from 30,715 women in 2018/19 (prior screening modality group) and 25,924 women in 2020/21 (updated screening modality group). In 2018/19, a total of 93 histological examinations were performed, compared to 237 in 2020/21. In 2018/19, 52 cases of CIN III and 12 cases of CIN II were identified, while in 2020/21, 78 cases of CIN III and 31 cases of CIN II were detected. In contrast, while women with negative cytological findings in 2018/19 were typically not referred for further colposcopic or histological evaluation, the updated program enabled earlier detection and treatment of cases with diagnosed high-grade dysplasia based solely on a positive HPV test. Notably, 31 women who were diagnosed at an earlier stage based solely on a positive HPV test initially presented with a cytological Pap I result (negative for intraepithelial lesion or malignancy; NILM). Conclusions: Additional HPV co-testing within the updated German cervical cancer screening program resulted not only in high rates of high-grade dysplasia detection but also a rise in the number of colposcopic procedures. While negative follow-up HPV findings regularly showed remission of the original finding, incidence of high-grade dysplasia was usually linked to a positive HPV test.
Keywords: cervical cancer; screening; detection rate; Germany; HPV-test; Pap-test; cytology; Co-test; combined screening cervical cancer; screening; detection rate; Germany; HPV-test; Pap-test; cytology; Co-test; combined screening

Share and Cite

MDPI and ACS Style

Jung, L.; Klamminger, G.G.; Nigdelis, M.P.; Eltze, E. Impact of HPV Testing Based on the 2020 Update of the German Cervical Cancer Screening Program—Data from a Retrospective Monocentric Study. Cancers 2025, 17, 2024. https://doi.org/10.3390/cancers17122024

AMA Style

Jung L, Klamminger GG, Nigdelis MP, Eltze E. Impact of HPV Testing Based on the 2020 Update of the German Cervical Cancer Screening Program—Data from a Retrospective Monocentric Study. Cancers. 2025; 17(12):2024. https://doi.org/10.3390/cancers17122024

Chicago/Turabian Style

Jung, Leonard, Gilbert Georg Klamminger, Meletios P. Nigdelis, and Elke Eltze. 2025. "Impact of HPV Testing Based on the 2020 Update of the German Cervical Cancer Screening Program—Data from a Retrospective Monocentric Study" Cancers 17, no. 12: 2024. https://doi.org/10.3390/cancers17122024

APA Style

Jung, L., Klamminger, G. G., Nigdelis, M. P., & Eltze, E. (2025). Impact of HPV Testing Based on the 2020 Update of the German Cervical Cancer Screening Program—Data from a Retrospective Monocentric Study. Cancers, 17(12), 2024. https://doi.org/10.3390/cancers17122024

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop